重复接种会降低人类不同流感疫苗平台的抗体亲和力成熟。

Repeat vaccination reduces antibody affinity maturation across different influenza vaccine platforms in humans.

机构信息

Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, 20993, USA.

Division of Biostatistics, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, 20993, USA.

出版信息

Nat Commun. 2019 Jul 26;10(1):3338. doi: 10.1038/s41467-019-11296-5.

Several vaccines are approved in the United States for seasonal influenza vaccination every year. Here we compare the impact of repeat influenza vaccination on hemagglutination inhibition (HI) titers, antibody binding and affinity maturation to individual hemagglutinin (HA) domains, HA1 and HA2, across vaccine platforms. Fold change in HI and antibody binding to HA1 trends higher for H1N1pdm09 and H3N2 but not against B strains in groups vaccinated with FluBlok compared with FluCelvax and Fluzone. Antibody-affinity maturation occurs against HA1 domain of H1N1pdm09, H3N2 and B following vaccination with all vaccine platforms, but not against H1N1pdm09-HA2. Importantly, prior year vaccination of subjects receiving repeat vaccinations demonstrated reduced antibody-affinity maturation to HA1 of all three influenza virus strains irrespective of the vaccine platform. This study identifies an important impact of repeat vaccination on antibody-affinity maturation following vaccination, which may contribute to lower vaccine effectiveness of seasonal influenza vaccines in humans.

美国每年批准几种疫苗用于季节性流感接种。在这里，我们比较了重复接种流感疫苗对血凝抑制（HI）效价、抗体结合和针对单个血凝素（HA）结构域、HA1 和 HA2 的亲和力成熟的影响，这些疫苗平台各不相同。与 FluCelvax 和 Fluzone 相比，FluBlok 组接种的 H1N1pdm09 和 H3N2 的 HI 和抗体结合对 HA1 的变化趋势更高，但对 B 株则不然。所有疫苗平台接种后，均可针对 H1N1pdm09、H3N2 和 B 的 HA1 域发生抗体亲和力成熟，但不能针对 H1N1pdm09-HA2。重要的是，接受重复接种的受试者在前一年接种疫苗会导致对所有三种流感病毒株的 HA1 的抗体亲和力成熟降低，而与疫苗平台无关。本研究确定了重复接种对接种后抗体亲和力成熟的重要影响，这可能导致季节性流感疫苗在人类中的有效性降低。